Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Buy" from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have earned a consensus rating of "Buy" from the eight ratings firms that are covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $24.67.

Several analysts have recently commented on STOK shares. Chardan Capital reaffirmed a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares of the company's stock, valued at $1,285,353.51. This trade represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,532 shares of company stock worth $143,332. Corporate insiders own 11.30% of the company's stock.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently modified their holdings of STOK. GAMMA Investing LLC boosted its stake in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after acquiring an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Stoke Therapeutics in the 4th quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new position in shares of Stoke Therapeutics in the fourth quarter valued at approximately $113,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Stoke Therapeutics during the 4th quarter worth $124,000. Finally, Tower Research Capital LLC TRC lifted its position in Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after buying an additional 4,918 shares during the period.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK traded up $0.13 during trading on Wednesday, reaching $7.69. The stock had a trading volume of 837,492 shares, compared to its average volume of 712,741. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $17.58. The stock has a market cap of $415.86 million, a PE ratio of -3.66 and a beta of 1.09. The business has a fifty day moving average price of $7.90 and a 200-day moving average price of $10.35.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Sell-side analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.